Enhancing the anti-ageing capacity of hUC-MSCs via NMN co-treatment in D-galactose-induced ageing mice and cellular senescence models.
Key claim: Co-administration of hUC-MSCs and NMN outperformed either alone against D-galactose-induced aging in mice by protecting transplanted MSCs from senescence via Nrf2/HO-1 activation.
Abstract
Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) have emerged as a promising therapeutic option for anti-ageing therapy. However, the ageing microenvironment can induce oxidative stress and senescence in transplanted hUC-MSCs, thereby impairing their capacity to delay immunosenescence. Combining MSC-based therapy with antioxidants may enhance therapeutic efficacy. This study explored whether hUC-MSCs could exert enhanced anti-immunosenescence effects when administered in combination with nicotinamide mononucleotide (NMN). Compared with either treatment alone, the combined administration exerted enhanced anti-ageing efficacy, as evidenced by marked alleviation of thymic and splenic atrophy, attenuation of body weight loss, and significant improvement in motor and cognitive functions in D-galactose-induced ageing mice. In vitro results indicated that combined treatment with hUC-MSCs and NMN alleviated cellular senescence in lymphocytes while simultaneously reducing oxidative stress and senescence in hUC-MSCs. Mechanistically, activation of the Nrf2/HO-1 pathway by NMN mitigated hUC-MSC senescence under stress conditions, thereby preserving their anti-ageing properties. Taken together, our study provides a promising combinatorial approach that sustains stem cell function and amplifies anti-ageing efficacy.
Why this matters
Stem cell infusions and NAD+ precursors like NMN are two of the most heavily marketed longevity-clinic offerings, usually sold as standalone protocols. This preclinical study is an early signal that the two might be mechanistically complementary — transplanted MSCs may senesce quickly without antioxidant support — which is likely to be picked up as marketing justification for stacked clinic packages well before any human combination trial exists.